NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1943
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DESOXYN (methamphetamine hydrochloride) by Hikma is 12. First approved in 1943.
Drug data last refreshed 15h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESOXYN is methamphetamine hydrochloride, an oral CNS stimulant approved since 1943 for ADHD treatment. It works by blocking reuptake of norepinephrine and dopamine into presynaptic neurons, increasing monoamine release in the extraneuronal space. The drug is formulated as an extended-release tablet for once-daily dosing.
LOE Approaching
As a legacy product approaching loss of exclusivity with low competitive pressure (30%), the team is likely consolidating and focused on operational efficiency rather than growth initiatives.
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in the treatment of ADHD is not known. 12.2 Pharmacodynamics Amphetamines block the reuptake of norepinephrine and dopamine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DESOXYN as a pharma professional typically involves managing a mature, highly regulated Schedule II product with constrained growth and reimbursement challenges. Career advancement on this asset is limited; professionals are better positioned in roles emphasizing operational excellence, regulatory compliance, and cash flow management rather than commercial expansion.
Worked on DESOXYN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.